Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later A. George Awad Current Opinion 03 December 2018 Pages: 1 - 8
Opioidergic Agents as Antidepressants: Rationale and Promise Parnika P. SaxenaJ. Alexander Bodkin Leading Article 15 November 2018 Pages: 9 - 16
Impact of Antidepressant Use on the Trajectory of Alzheimer’s Disease: Evidence, Mechanisms, and Therapeutic Implications Rita KhouryGeorge T. Grossberg Review Article 19 November 2018 Pages: 17 - 29
Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa Susan L. McElroyAnna I. GuerdjikovaFrancisco Romo-Nava Review Article 06 December 2018 Pages: 31 - 46
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. SandsShahryar RahdariMaria Roberta Cilio Original Research Article 20 November 2018 Pages: 47 - 60
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine Jeremy HobartTjalf ZiemssenOn behalf of the ENHANCE study investigators Original Research Article Open access 10 December 2018 Pages: 61 - 79
Effects of Clozapine on the Gut: Cross-Sectional Study of Delayed Gastric Emptying and Small and Large Intestinal Dysmotility Susanna Every-PalmerStephen J. InnsPete M. Ellis Original Research Article 19 November 2018 Pages: 81 - 91
Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis Dimitrios PapadopoulosDimos-Dimitrios D. Mitsikostas Correction 20 December 2018 Pages: 93 - 97